ClinicalTrials.gg
RecruitingNCT00493688Updated Jul 15, 2026

A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

An observational study in Abdominal Cancer and Pelvic Cancer, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

From the registry’s dates

  • Started Oct 2005; still recruiting 21 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Pelvic Neoplasms with a site in United States — 5 open to participants now, 9 under way, 2 of them phase 3. Pelvic Neoplasms · United States.

Started
2005
the only one that year
Observational
8 of 28
2 open now
Registered
8th of 28
by date
Lead sponsor
3 of 28
M.D. Anderson Cancer Center

Among the 28 studies in Pelvic Neoplasms with a site in United States, this one is the only one that started in 2005, is one of 8 observational ones, and was the 8th registered.

Pelvic Neoplasms

82 studies on the registry are indexed under Pelvic Neoplasms; 28 are open to participants now.

Browse Pelvic Neoplasms studies →

Open to participants now

5 of the 28 studies in Pelvic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Pelvic Neoplasms studies recruiting now, 16 (70%) set no upper age limit and 3 (13%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Pelvic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

To validate a new method for assessing perioperative risk in the cancer patient undergoing major cancer surgery.

In this proposed study researchers will:

  1. Measure preoperative energy reserve capacity (fitness)
  2. Determine if postoperative morbidity is a function of perioperative cardiopulmonary gas exchange metabolism
Read the detailed description

Primary Objective:

  • To characterize the effects of neoadjuvant therapy (chemotherapy, radiation therapy, and/or immunotherapy) on functional capacity in esophageal and lung cancer participants as measured by gas exchange parameters (%predicted AT, %predicted P-VO2, VO2 at AT \& peak exercise, oxygen pulse, ΔVO2/ΔWR, ΔVE/ΔVCO2) obtained from CPET before and after neoadjuvant therapy.

Secondary Objectives:

  • To characterize changes in CPET measures in participants treated with chemotherapy, radiation therapy, and/or immunotherapy followed by surgery and correlate these changes with postoperative outcome.
03

Conditions studied

  • Abdominal Cancer
  • Pelvic Cancer

Browse trials for

Keywords

  • Abdominal Cancer
  • Pelvic Cancer
  • Perioperative Energy Dynamics
  • Cardiopulmonary Exercise Testing
  • CPET
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Individuals scheduled for elective major intrabdominal surgery or pelvic surgeries surgeries (e.g. gastrectomy, esophagectomy, pancreatectomy, radical cystectomy, radical transabdominal debulking with or without intrabdominal hyperthermic perfusion, pelvic exenteration, retroperitoneal lymph node dissections, and low anterior resection).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants 18 years of age or older.
  • Participants with newly diagnosed esophageal and lung cancer undergoing chemotherapy, radiation therapy, and/or immunotherapy.
  • Participants who have signed the consent form to participate in the study.
  • Participants must have been evaluated in the Perioperative Evaluation and Management (POEM) Center or by a staff Anesthesiologist.
  • All laboratory and diagnostic evaluations required or used to evaluate the patient must be completed. All participants must be approved to undergo anesthesia by the standards of the POEM Center.
  • No samples belonging to vulnerable populations (children, pregnant women, cognitively impaired adults or prisoners) will be allowed from participation.

Exclusion criteria

Exclusion Criteria:

  • Participant is under age 18.
  • Participant is unwilling to sign consent.
  • Participant is unable to exercise (bedridden or wheel chair bound).
  • Participant is enrolled in another study deemed by the investigator to affect oxygen metabolic efficiency and not presently the standard of care at MDACC.
  • Participant's condition is deemed unsatisfactory for surgery after the preanesthetic evaluation.
  • Participant has had a myocardial infarction within three months of the preanesthetic evaluation or presents with new or unstable angina.
  • Participant has a history of a cerebrovascular accident or transit ischemic attacks within three months of the preanesthetic evaluation.
  • Participant has a history of a pulmonary embolic event within three months of the preanesthetic evaluation.
  • Participant is known to have acute or chronic deep vein thrombosis.
  • Participant is pregnant.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)

Groups and cohorts

  • Cardiopulmonary Exercise Testing (CPET)

    Other: Cardiopulmonary Exercise Testing (CPET)

Interventions

  • OtherCardiopulmonary Exercise Testing (CPET)

    Pedaling on a Stationary Bicycle at 60 Revolutions Per Minute as the Resistance to Pedaling Gradually Increases.

06

What researchers measure

Primary outcomes

  1. Patient Perioperative Risk

    Measure preoperative energy reserve capacity (fitness) using perioperative energy dynamics where fitness is defined by gas exchange data during cardiopulmonary exercise testing as method of assessing perioperative risk

    Time frame: Baseline + 30 days postoperatively monitoring for morbid events

07

Study locations

1 of 1 sites recruiting
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • MD Anderson General Health Specialist · Contact877-632-6789
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2005 (actual). Primary completion is estimated for Oct 2028, 276 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2007
First posted
Jun 28, 2007
StartActual
Oct 30, 2005
Primary completionEst.
Oct 30, 2028
CompletionEst.
Oct 30, 2028
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00493688
Responsible party
Sponsor
First posted
Jun 28, 2007
Start date
Oct 30, 2005
Primary completion
Oct 30, 2028 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Jul 15, 2026

Study contacts

Anh Q Dang, MD
Contact
adang@mdanderson.org
713-745-5025
Anh Dang, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion